Key Takeaway: In a recent interview on The Big Biz Show, Jonathan C. Javitt, M.D., M.P.H., discussed the promising applications of Ketamine in treating acute suicidality and chronic pain. He highlighted NRX-101, an oral medication aimed at depression, and elaborated on the role of dopamine as a neurotransmitter. The interview also touched on a recent investor workshop held at the Mar-A-Lago Club.
Price reaction · baseline $4.26 (2025-01-16 close) · hit pre-market · 1 other NRXP headline(s) in the window, move may be shared
day 0 close
-5.9%
day 1
-17.1%
day 3 · peak
-31.2%
Market Sentiment Analysis
POSITIVE FACTORS
Discussion on innovative treatments for acute suicidality.
Focus on the potential of NRX-101 as an oral medication.
Engagement with investors at a prestigious venue.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+167%
120-day peak, hindsight
Typical move
4.3%
average across 2 past catalysts
Cash runway
~12 mo
Low dilution risk
Lead asset
NRX-101
Phase 2 · Bipolar Depression
Full Press Release Details
The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H. Founder, Chairman and CEO of NRx Pharmaceuticals and Co-CEO of HOPE Therapeutics discussing applications of Ketamine and it’s treatment for acute suicidality, anti-depressant/chronic pain oral medication NRX-101, how dopamine acts as a neurotransmitter in the brain and the recent investor workshop at the Mar-A-Lago Club.
Frequently Asked Questions
What is NRX-101?
NRX-101 is an oral medication developed for treating depression and chronic pain.
Who is Jonathan C. Javitt?
Jonathan C. Javitt is the Founder, Chairman, and CEO of NRx Pharmaceuticals.
What was discussed in the interview?
The interview covered Ketamine's applications and its role in treating acute suicidality.
Where was the recent investor workshop held?
The investor workshop took place at the Mar-A-Lago Club.